The Cancer That Disappeared in Every Single Patient

These aren't just good numbers. For a single-arm phase 2 trial, they're extraordinary.

Why This Matters Beyond the Data

To understand the significance, you need to understand what standard treatment for locally advanced rectal cancer looks like. Think of it as a three-course meal nobody wants to eat: chemotherapy, radiation, and then major surgery that often involves removing part (or all) of the rectum.

The side effects can be permanent. Bowel dysfunction. Urinary problems. Sexual dysfunction. Fertility loss. Even secondary cancers from the radiation itself. For patients who are cured, the quality-of-life toll can be devastating. It's a treatment paradigm that works, but at a brutal cost.

Dostarlimab offers something radically different: an organ-preserving approach. Patients receive the drug as an infusion every three weeks for six months. If the cancer disappears (and in this population, it very often does), that's it. No chemo, no radiation, no scalpel. Your body stays intact.

This is the first and only immunotherapy approved in the U.S. for this specific rectal cancer subgroup, and it represents a genuine shift in how we think about treating cancer. Instead of defining treatment by where the tumor sits, this approval defines it by the tumor's molecular signature: its dMMR/MSI-H status, confirmed by an FDA-authorized test.

The Fine Print Worth Reading

A few important caveats. First, this is an accelerated approval, which means the FDA was convinced enough by the data to let patients access the drug now, but GSK still needs to provide confirmatory evidence. Continued approval could depend on what that longer-term data shows.

Second, the eligible population is narrow. Only about 3% to 10% of rectal cancers are dMMR/MSI-H, depending on the study you cite. Globally, rectal cancer affects roughly 700,000 people per year, so we're talking about tens of thousands of patients worldwide who might qualify. It's meaningful, but it's not a mass-market indication.

Third, the drug isn't side-effect free. The most common adverse reactions were fatigue, rash, diarrhea, and itching. And like all checkpoint inhibitors (drugs that release the brakes on the immune system), dostarlimab can trigger immune-mediated reactions that range from manageable to severe.

What It Means for GSK's Bottom Line

Jemperli was already on a tear before this approval. The drug pulled in £861 million (roughly $1.13 billion) in 2025 sales, growing 89% year over year. That growth was fueled mostly by its earlier approval in endometrial cancer, where it became a go-to treatment after the FDA and EMA expanded its label.

The rectal cancer indication is comparatively small, but it carries outsized strategic value. It positions Jemperli as the flagship example of precision oncology done right: matching the drug to a biomarker, not just a body part. That kind of story resonates with prescribers, payers, and investors alike.

GSK's overall oncology business hit just under £2 billion in 2025. The drug is now firmly in blockbuster territory with room to grow.

The Bigger Bet on Precision Oncology

Step back and this approval tells a larger story about where cancer treatment is heading. The old model grouped patients by organ: lung cancer patients got lung cancer drugs, colon cancer patients got colon cancer drugs. The new model is increasingly biomarker-first. If your tumor has a specific molecular defect, you might get the same immunotherapy whether that tumor is in your rectum, your uterus, or your stomach.

Dostarlimab's journey from a jaw-dropping 14-patient pilot to a full FDA approval is proof of concept for that vision. And for the thousands of rectal cancer patients each year who carry the dMMR/MSI-H marker, it's something simpler and more profound: a chance to beat cancer without losing a part of themselves in the process.

EyePoint's Wet AMD Drug Failed Twice. Then Came the Pink Slips.

EyePoint Pharmaceuticals failed its second Phase 3 wet AMD trial in two months, triggering an 85% stock crash and layoffs for more than half its workforce. The double miss is the latest cautionary tale in a sector that punishes clinical ambiguity with existential consequences.